Home > Dermatology > WCD 2019 > Small Molecules – What to Expect > Long awaited oral therapy for moderate-to-severe AD

Long awaited oral therapy for moderate-to-severe AD

Presented By
Prof. Thomas Bieber, University Medical Center Bonn, Germany
WCD 2019

There is an urgent need for a non-steroid oral therapy for patients, particularly paediatric patients, with severe atopic dermatitis (AD). Small molecules could be the solution.

A couple of small molecules are in the pipeline for moderate-to-severe AD, such as several Janus kinase (JAK) inhibitors, began Prof. Thomas Bieber (University Medical Center Bonn, Germany) in his presentation [1]. In a phase 2b trial, the selective JAK1 inhibitor upadacitinib showed promising results [2]. Patients inadequately controlled by topical treatment, or for whom topical treatments were not medically advisable were randomised to once-daily upadacitinib monotherapy in 3 doses or placebo. The primary endpoint of this study was the mean percentage improvement in Eczema Area and Severity Index (EASI) score from baseline to week 16. At week 16, all upadacitinib dose groups experienced statistically significant improvements compared with placebo. Mean EASI scores improved 23% fo...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on